Allogene Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock
Key Highlights for Investors:
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) has announced the commencement of a proposed underwritten public offering of its common stock.
- Offering Suspension: In connection with this proposed public offering, Allogene has suspended the ongoing “at-the-market” (ATM) program under its sales agreement prospectus dated April 25, 2024, which was part of its Registration Statement on Form S-3 (File No. 333-277951). This registration relates to the Sales Agreement with TD Securities (U.S.A.) LLC, formerly known as Cowen and Company, LLC, originally dated November 5, 2019, and amended in 2022 and 2023.
- No Further Sales Under ATM Program: The company will not make any further sales of common stock under the ATM Sales Agreement unless and until a new prospectus or prospectus supplement is filed with the SEC.
- Legal Disclosures: The 8-K filing makes clear that the current report does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the company. Any such offer will only be made by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Details of the Proposed Offering
The proposed underwritten public offering is a significant event for Allogene, as it provides an opportunity for the company to raise additional capital. The specifics of the size, price, and use of proceeds of the offering have not yet been disclosed, as is typical at the commencement stage. Investors should monitor for further announcements and filings, including the prospectus supplement, which will contain detailed terms of the offering.
Potential Shareholder Impact and Price-Sensitive Considerations
- Capital Raise Implications: The announcement of a public offering typically signals the company’s intent to strengthen its balance sheet, fund ongoing operations, or invest in strategic initiatives. However, such offerings may result in share dilution, which can impact existing shareholders’ ownership percentages and potentially influence the share price.
- Suspension of ATM Program: The suspension of the ATM program means the company will not sell additional shares under that agreement until a new prospectus is filed. This may affect near-term supply and demand dynamics for ALLO shares.
- Regulatory Compliance: The company is taking steps to ensure all sales are compliant with securities regulations, specifically referencing that no offers or sales will occur in jurisdictions where such actions would be unlawful.
- Board and Management Actions: The report is signed by David Chang, M.D., Ph.D., President and Chief Executive Officer, reflecting executive oversight and authorization of the actions disclosed.
Company and Security Information
- Name: Allogene Therapeutics, Inc.
- Trading Symbol: ALLO
- Exchange: The Nasdaq Global Select Market
- Business Address: 210 East Grand Avenue, South San Francisco, CA 94080
- Telephone: (650) 457-2700
- Legal Incorporation: State of Delaware
- Employer Identification Number (EIN): 82-3562771
What Investors Should Watch For
- Details of the underwritten public offering, including the number of shares to be offered, the offering price, and the intended use of proceeds, are expected to be announced in forthcoming filings and press releases.
- Potential dilution from the offering could impact the share price, but the capital raised may also fund clinical development, research, or other corporate objectives that could benefit long-term shareholders.
- Monitor for new filings of a prospectus or prospectus supplement, which will enable the company to resume sales under the ATM program if desired.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors prior to making any investment decisions. Allogene Therapeutics, Inc.’s proposed public offering and suspension of its ATM program are subject to risks and uncertainties, including market conditions and regulatory approvals.
View Allogene Therapeutics, Inc. Historical chart here
